latest update:
[TrialBase DB]

trial summary · NCT07882160

Metabolic Impact of VLCPUFA-Rich Fish Oil: A Clinical Study on Omega-3 Index Enhancement in Healthy Individuals

Trial record from the TrialBase DB dataset, status RECRUITING, condition Fatty Acids, Omega-3, sponsored by National Heart, Lung, and Blood Institute (NHLBI). Facts below are exported values from the current release, not inferred or edited prose.

registry NCT07882160phase —enrollment 200start 2026-11-04

Summary

The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.

Background: Fish oils contain omega-3 fatty acids that play important roles in the body. Researchers are studying a new type of fish oil that contains very-long-chain omega-3 fatty acids (VLCPUFAs). They want to learn how this fish oil affects omega-3 levels in the blood and other measures related to health. Objective: To learn how a VLCPUFA-enriched fish oil changes omega-3 levels in the blood compared with a standard fish oil. Eligibility: Healthy adults ages 18 to 60 years with a body mass index (BMI) between 18 and 30 kg/m\^2 may be eligible. Design: Participants will take part in the study for about 28 to 30 weeks and will have approximately 4 to 5 clinic visits plus a follow-up phone call. Participants will complete screening tests to determine whether they are eligible. These may include a physical examination, blood tests, measurement of height and weight, visual testing, cognitive testing, and questions about their diet, exercise, medications, and daily habits. Participants will take 2 fish oil capsules by mouth every day for 8 weeks. They will then stop taking study capsules for about 12 weeks. After that, they will take a different fish oil capsule for another 8 weeks. One fish oil contains very-long-chain omega-3 fatty acids (VLCPUFAs), and the other contains standard omega-3 fatty acids. Participants will not know which type they are taking during each study period. Blood samples and other study assessments will be collected at the beginning and end of each treatment period to measure changes in omega-3 levels and other study markers. Participants will receive …

Source record: https://clinicaltrials.gov/study/NCT07882160

Facts

registry idNCT07882160
primary registryclinicaltrials-gov
recruitment statusRECRUITING
phasenot reported
study typeINTERVENTIONAL
lead conditionFatty Acids, Omega-3
sponsorNational Heart, Lung, and Blood Institute (NHLBI)
sponsor classNIH
enrollment200
start date2026-11-04
primary completion2027-12-01
completion2027-12-01
results postednot reported

Conditions

  • Fatty Acids, Omega-3
  • Fish Oils

Interventions

  • VLCPUFA-rich fish oil
  • DHA-rich fish oil

Countries

  • United States

Intervention types: DIETARY_SUPPLEMENT

Work with this record